| Literature DB >> 35077610 |
Tali Cassidy1,2,3, Morna Cornell4, Pumeza Runeyi1, Thembie Dutyulwa1, Charllen Kilani1, Laura Trivino Duran1, Nompumelelo Zokufa1, Virginia de Azevedo5, Andrew Boulle4,6, C Robert Horsburgh3,7,8, Matthew P Fox3,8,9.
Abstract
INTRODUCTION: Youth living with HIV (YLWH) are less likely to initiate antiretroviral therapy (ART) and remain in care than older adults. It is important to identify effective strategies to address the needs of this growing population and prevent attrition from HIV care. Since 2008, two clinics have offered youth-targeted services exclusively to youth aged 12-25 in Khayelitsha, a high HIV-prevalence, low-income area in South Africa. We compared ART attrition among youth in these two clinics to youth in regular clinics in the same area.Entities:
Keywords: HIV; antiretroviral therapy; differentiated service delivery; retention in care; youth
Mesh:
Substances:
Year: 2022 PMID: 35077610 PMCID: PMC8789247 DOI: 10.1002/jia2.25854
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Summary of characteristics and services of Youth Clinic A, Youth Clinic B and general clinics
| Youth Clinic A | Youth Clinic B | General clinics | |
|---|---|---|---|
| Target population | Exclusively youth between 12 and 25 years old | All age groups | |
| HIV services | HIV testing, counselling, ART initiation and management | ||
| Other services | Contraception, TB and STI screening and basic curative services |
Contraception, TB and STI screening and basic curative services TB treatment initiation and management | |
| Counselling | Counselling before and after HIV testing, and adherence counselling is provided by lay adherence counsellors, a key cadre supporting the retention of ART patients [ | ||
| Health authority | City of Cape Town Department of Health | ||
| Adherence clubs |
Peer support from other youth, differentiating between youth of school‐going age and those over the age of 18 Can be joined immediately after ART initiation Integrated family planning services |
Peer support from other youth Eligible 6–12 months after initiation |
Peer support from other patients (not differentiated by age) Eligible 6–12 months after initiation |
| Transition | Transfer to general clinic when turning 26, usually main clinic on same premises (see “structure” below) | Transfer to general clinic when turning 26, usually main clinic on nearby premises (see “structure” below) | Not needed |
| Visits | Visits are typically spaced 1 month apart when patients initiate and 2 months apart for stable patients and patients in adherence clubs. Before the holiday period (December–January), patients may receive 4 months of medication. | ||
| Pharmacy | For patients not in adherence clubs, ART is collected from an on site pharmacy after their clinical visit. | ||
| Records | Captured into PREHMIS and electronic medical records system from patient folders after patients attend a visit. Folders are stored on site and captured by data clerks at the clinics. | ||
| Structure | Standalone building on premises of larger clinic | Standalone building on premises near larger clinic | Standalone buildings on clinc premises |
|
Geographic location (all within Khayelitsha) |
Khayelitsha Located in Site C, a dense, largely informal area |
Khayelitsha Located in Site B, a dense, largely informal area |
Khayelitsha Variety of areas across Khayelitsha |
| Médecins Sans Frontières involvement 2008–2010 | Supported | Supported | Not specifically supporting youth services |
| Médecins Sans Frontières involvement after 2010 | Managed counsellors | Handed over | Not specifically supporting youth services |
Figure 1Flow chart for inclusion in analysis.
Distribution of covariates by clinic group, after imputation (before and after propensity score matching)
| General clinics (before matching) | Youth Clinic A | Matched controls | Youth Clinic B | Matched controls | |
|---|---|---|---|---|---|
|
| 3056 | 1383 | 1383 | 1299 | 1299 |
| Era of ART initiation | |||||
| Eligibility CD4<200 (before August 2011) | 11% | 16% | 14% | 23% | 18% |
| Eligibility CD4<350 (August 2011–31 December 2014) | 31% | 31% | 33% | 31% | 37% |
| Eligibility <500 (1 January 2015–31 August 2016) | 29% | 25% | 24% | 24% | 24% |
| All eligible (1 September 2016) | 28% | 28% | 28% | 22% | 22% |
| Age | |||||
| 12–17 years | 9% | 8% | 9% | 9% | 9% |
| 18–25 years | 91% | 92% | 91% | 91% | 91% |
| Median age (years) (IQR) | 22.4 (20.4–23.8) | 22.2 (20.4–23.5) | 22.4 (20.4–23.8) | 21.8 (20–23.3) | 22.5 (20.4–23.8) |
| Sex | |||||
| Male | 11% | 11% | 11% | 9% | 11% |
| Baseline WHO Stage | |||||
| Stage 1 | 71% | 80% | 82% | 75% | 77% |
| Stage 2 | 16% | 14% | 11% | 11% | 11% |
| Stage 3 | 10% | 5% | 5% | 11% | 10% |
| Stage 4 | 3% | 1% | 1% | 3% | 2% |
| Stages 2–4 | 29% | 20% | 18% | 25% | 23% |
| Baseline CD4 count (cells/mm3) | |||||
| <100 | 9% | 6% | 8% | 9% | 10% |
| 100–199 | 15% | 16% | 16% | 15% | 16% |
| 200–349 | 33% | 40% | 34% | 36% | 36% |
| 350–500 | 24% | 21% | 23% | 23% | 21% |
| >500 | 19% | 17% | 20% | 17% | 17% |
| Median CD4 count (IQR) | 318 (205–460) | 303 (211–435) | 315 (204–459) | 310 (203–438) | 304 (194–438.1) |
| ART regimen at initiation | |||||
| EFV‐free regimens | 6% | 9% | 8% | 11% | 9% |
| TFV‐free regimens | 9% | 10% | 10% | 11% | 12% |
| Adherence clubs | |||||
| Ever in club at clinic (before age 26) | 19% | 20% | 19% | 13% | 18% |
| Median months in club (before age 26) | 16.7 (6.3–25.8) | 11.7 (4.6–21.1) | 10.1 (1.8–20.5) | ||
| Median months on ART before club | 23.7 (12.7–45.8) | 10.6 (3.6–20.1) | 21.4 (14–36.8) | ||
| % 6‐month attrition | 21% | 15% | 20% | 17% | 20% |
Abbreviations: EFV, Efavirenz; TFV, Tenofovir.
Attrition from care at 6 and 12 months by covariates (without imputation or propensity score matching)
| Attrition by 6 months | Attrition by 12 months | |
|---|---|---|
|
|
| |
| Total | 19% | 25% |
| Exposure group | ||
| General clinics | 21% | 27% |
| Youth Clinic A | 15% | 22% |
| Youth Clinic B | 17% | 24% |
| Sex | ||
| Male | 18% | 24% |
| Female | 19% | 25% |
| Era of ART initiation (by CD4 count eligibility criteria) | ||
| <200 (before August 2011) | 11% | 18% |
| <350 (August 2011–31 December 2014) | 16% | 22% |
| <500 (1 January 2015–31 August 2016) | 19% | 27% |
| All eligible (after 1 September 2016) | 28% | 35% |
| Age | ||
| 12–17 years | 16% | 22% |
| 18–25 years | 19% | 26% |
| WHO Stage at initiation | ||
| Stage 1 | 19% | 26% |
| Stage 2 | 14% | 18% |
| Stage 3 | 14% | 19% |
| Stage 4 | 23% | 28% |
| Stages 2–4 | 15% | 19% |
| Stage missing | 29% | 36% |
| Baseline CD4 count (cells/mm3) | ||
| <100 | 17% | 26% |
| 100–199 | 15% | 19% |
| 200–349 | 17% | 23% |
| 350–500 | 21% | 29% |
| >500 | 23% | 30% |
| CD4 count missing | 19% | 28% |
| ART regimen at initiation | ||
| EFV‐free regimens | 11% | 15% |
| TFV‐free regimens | 12% | 17% |
| TFV‐EFV regimens | 19% | 26% |
| Missing regimen information | 29% | 38% |
| Ever in adherence club at clinic | 0% | 2% |
| Never in adherence club at clinic | 23% | 31% |
6‐month retention is only presented for those who initiate ART more than 9 months before dataset closure.
12‐month retention is only presented for those who initiate ART more than 15 months before dataset closure.
Figure 2Kaplan–Meier survival estimates for matched cohorts, by clinic type.
Cox regression models of attrition risk of youth clinic compared to general clinic patients
| Method | Variables adjusted for/included in propensity score model | HR of risk of attrition in youth clinic versus general clinics (95% CI) | |
|---|---|---|---|
| Youth Clinic A | Youth Clinic B | ||
| Full cohort analyses |
|
| |
| Matched propensity score approach | Start date and WHO Disease Stage | 0.81 (0.71–0.92) | 0.85 (0.74–0.98) |
| Guideline era and WHO Disease Stage | 0.74 (0.65–0.84) | 0.90 (0.78–1.03) | |
| No matching, combined Cox model, including Youth Clinic A and B | Crude | 0.78 (0.69–0.88) | 0.80 (0.71–0.90) |
| Adjusting for start date | 0.80 (0.71–0.91) | 0.86 (0.76–0.97) | |
| Adjusting for ART start date, WHO Stage | 0.81 (0.72–0.92) | 0.87 (0.77–0.98) | |
|
| |||
| Matched propensity score approach | Start date and WHO Disease Stage | 0.68 (0.60–0.76) | 0.72 (0.64–0.81) |
| Guideline era and WHO Disease Stage | 0.62 (0.55–0.70) | 0.75 (0.66–0.85) | |
| No matching, combined Cox model, including Youth Clinic A and B | Crude | 0.66 (0.59–0.73) | 0.68 (0.61–0.75) |
| Adjusting for start date | 0.67 (0.60–0.75) | 0.71 (0.64–0.79) | |
| Adjusting for ART start date, WHO Stage | 0.68 (0.61–0.75) | 0.72 (0.64–0.80) | |
| Adherence club patients only ( | |||
| No matching, combined Cox model, including Youth Clinic A and B | Crude | 0.56 (0.32–0.96) | 0.83 (0.48–1.45) |
| Adjusting for start date | 0.49 (0.28–0.84) | 0.98 (0.56–1.72) | |
| Adjusting for ART start date, WHO Stage | 0.49 (0.28–0.85) | 0.98 (0.56–1.72) | |
| Adjusting for ART start date, WHO Stage and age at club start | 0.50 (0.29–0.88) | 1.00 (0.57–1.77) | |
| Adjusting for ART start date, WHO Stage, age at club start and time on ART at club start | 0.48 (0.28–0.85) | 1.07 (0.60–1.90) | |
|
| |||
| No matching, combined Cox model, including Youth Clinic A and B | Crude | 0.50 (0.30–0.85) | 0.58 (0.32–1.06) |
| Adjusting for start date | 0.48 (0.28–0.83) | 0.61 (0.33–1.12) | |
| Adjusting for ART start date, WHO Stage | 0.49 (0.29–0.85) | 0.60 (0.33–1.10) | |
| Adjusting for ART start date, WHO Stage and age at club start | 0.49 (0.28–0.84) | 0.60 (0.32–1.09) | |
| Adjusting for ART start date, WHO Stage, age at club start and time on ART at club start | 0.48 (0.28–0.82) | 0.63 (0.34–1.17) | |
Analyses conducted separately for Youth Clinic A and B.
Analysis of full dataset, including Youth Clinic A and B, with general clinics as reference group.
The first time there is a 9‐month gap in care patients are considered lost to follow‐up even if they return to care, with the date of last visit before the gap in care being the outcome date.